Introgen Therapeutics, Inc. will present data and update the results of clinical trials from Advexin p53 therapy used in recurrent head and neck cancer. The data will be concurrently presented at the annual meetings of the American Society of Gene Therapy and the American Society of Clinical Oncology.

Additionally, the company will present data from its Li-Fraumeni Cancer programme in which Advexin is used to successfully treat inherited cancer. Introgen recently announced it will provide Advexin p53 therapy for compassionate use to treat qualified cancer patients suffering from Li- Fraumeni Syndrome.

During presentations at the ASGT meeting and at an ASCO-sanctioned symposium, Introgen and its clinical collaborators will discuss clinical trial results and findings related to a set of prognostic indicators associated with high response rates and increased survival of Advexin patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).

Also to be presented are the results of a phase 1 trial, conducted in Japan, of Advexin in patients with advanced non-small cell cancer. In addition to Advexin data, results from studies involving INGN 241 (mda-7/IL24 therapy) and INGN 007 viral cancer therapy programmes will be presented.

Advexin p53 therapy is a targeted molecular therapy with broad applicability in a wide range of tumour types and clinical settings because it targets one of the most fundamental and common molecular defects, abnormal p53 tumour suppressor function, associated with cancer initiation, progression and treatment resistance. Prognostic biomarkers can identify patients most likely to respond to Advexin. Advexin has been studied worldwide in a number of solid tumour types in multiple phase 1, 2 and 3 clinical trials.